Inventage Lab Inc is a Korea-based company principally engaged in the pharmaceutical business. The Company owns the platforms applied to the development and mass production of long-acting injections and drug delivery of genetic materials. The Company is engaged in the research, manufacture and sale of human medicines used for male pattern baldness, dementia, prostate cancer and others. It is also engaged in the research, manufacture and sale of veterinary medicines such as combination drugs, chemical castration agents and others.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
18/08/26	₩30,100.00	-1.31%	22,275
18/08/26	₩30,500.00	-4.98%	45,719
14/08/26	₩32,100.00	-0.62%	52,577
13/08/26	₩32,300.00	+2.87%	39,433
12/08/26	₩31,400.00	-2.33%	34,800

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Korea S.E. 19/08/2026			5-day change	1st Jan Change
30,100.00 ^KRW	-1.31%		-6.38%	-64.25%

03-15	Quratis Inc. announced that it has received KRW 10.000000167 billion in funding from Inventage Lab, Inc.	CI
03-15	Inventage Lab, Inc. announced that it has received KRW 89.99724455 billion in funding from a group of investors	CI

Market Cap	400B 287M 247M 230M 211M 397M 27.48B 404M 2.72B 1.06B 13.78B 1.08B 1.06B 45.56B	P/E 2024	-11.5x	P/E 2025	-110x
Enterprise Value	394B 284M 243M 227M 208M 392M 27.11B 398M 2.68B 1.05B 13.6B 1.06B 1.04B 44.95B	EV / Sales 2024	106x	EV / Sales 2025	356x
Free-Float	73.58%	Yield 2024 *	-	Yield 2025	-

03-15	Quratis Inc. announced that it has received KRW 10.000000167 billion in funding from Inventage Lab, Inc.	CI
03-15	Inventage Lab, Inc. announced that it has received KRW 89.99724455 billion in funding from a group of investors	CI
03-08	Inventage Lab, Inc. announced that it has received KRW 8.5 billion in funding	CI
03-05	Inventage Lab, Inc. announced that it expects to receive KRW 37.25 billion in funding from a group of investors	CI
03-05	Inventage Lab, Inc. announced that it expects to receive KRW 8.5 billion in funding	CI
03-05	Inventage Lab, Inc. announced that it expects to receive KRW 52.74724455 billion in funding from a group of investors	CI
03-05	Quratis Inc. announced that it expects to receive KRW 10.000000167 billion in funding from Inventage Lab, Inc.	CI
02-25	Inventage Lab, Inc. agreed to acquire an additional 12.79% stake in Quratis Inc. for KRW 13.5 billion.	CI
12-10	Inventage Lab Seeks Approval for Phase 2 Trial of Alopecia Drug in Australia	MT
22/09/25	Inventage Lab, Inc.(KOSDAQ:A389470) added to S&P Global BMI Index	CI
11/03/25	Inventage Lab, Inc. announced that it has received KRW 9.9999925 billion in funding from PEACE to S KOREA Co., Ltd	CI
11/03/25	Quratis Inc. announced that it has received KRW 10.0329 billion in funding from Inventage Lab, Inc.	CI
20/02/25	Quratis Inc. announced that it has received KRW 15 billion in funding from Inventage Lab, Inc.	CI

1 day	-1.31%
1 week	-6.38%
Current month	+10.46%
1 month	-10.55%
3 months	-40.98%
6 months	-61.26%
Current year	-64.25%

Inventage Lab, Inc. Share Price

Stocks

A389470

KR7389470006

Pharmaceuticals

Valuation: Inventage Lab, Inc.

Chart: Inventage Lab, Inc.

Latest news : Inventage Lab, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Inventage Lab, Inc.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	29,300	34,650
1 month	22,650	34,650
Current year	22,650	101,700
1 year	22,650	101,700
3 years	9,400	101,700
5 years	8,440	101,700
10 years	8,440	101,700

Manager	Title	Age	Since
Ju-Hee Kim CEO	Chief Executive Officer	52	13/05/2015
Byeong-Yul Jeong DFI	Director of Finance/CFO	55	-
Chan-Hee Jeon CTO	Chief Tech/Sci/R&D Officer	57	-

Director	Title	Age	Since
Ju-Hee Kim BRD	Director/Board Member	52	13/05/2015
Choong-Ho Ryu BRD	Director/Board Member	56	-
Dong-Hoon Kim BRD	Director/Board Member	56	-

Date	Insider	Type	Quantity	% Market Cap.
08/08/25	Dong Seok Park	Fiscal year	8,000	0.0796%
08/08/25	Se Yeon Kim	Fiscal year	10,000	0.0996%
08/08/25	Dong Seok Park	Fiscal year	8,000	0.0796%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INVENTAGE LAB, INC.	-1.31%	-6.38%	-12.37%	+38.71%	287M
ELI LILLY AND COMPANY	+4.46%	+5.38%	+83.42%	+134.31%	1,093B
JOHNSON & JOHNSON	+0.85%	+5.24%	+55.13%	+58.51%	653B
ABBVIE INC.	+2.72%	+6.35%	+28.76%	+77.15%	458B
ROCHE HOLDING AG	+1.80%	-0.41%	+43.52%	+44.05%	355B
NOVARTIS AG	+1.24%	+1.00%	+26.84%	+42.21%	294B
ASTRAZENECA PLC	+2.07%	+1.74%	+2.66%	+13.06%	248B
AMGEN INC.	+4.02%	+6.77%	+51.17%	+68.96%	230B
NOVO NORDISK A/S	+1.05%	-2.52%	-13.83%	-52.13%	203B
GILEAD SCIENCES, INC.	+2.90%	+8.71%	+25.10%	+94.52%	178B
Average	+1.77%	+0.67%	+29.04%	+51.93%	371.08B
Weighted average by Cap.	+2.33%	+1.45%	+47.89%	+73.74%

	2024	2025
Net sales	1.78B 1.28M 1.1M 1.03M 942K 1.77M 123M 1.8M 12.12M 4.75M 61.48M 4.82M 4.71M 203M	2.94B 2.11M 1.81M 1.69M 1.55M 2.92M 202M 2.97M 19.98M 7.82M 101M 7.94M 7.76M 335M
Net income	-17B -12.23M -10.49M -9.79M -8.98M -16.89M -1.17B -17.17M -116M -45.25M -586M -45.9M -44.9M -1.94B	-8.46B -6.08M -5.22M -4.87M -4.47M -8.41M -582M -8.55M -57.5M -22.52M -292M -22.84M -22.35M -964M
Net Debt	-23.96B -17.24M -14.79M -13.81M -12.67M -23.82M -1.65B -24.21M -163M -63.8M -826M -64.72M -63.31M -2.73B	-5.33B -3.83M -3.29M -3.07M -2.82M -5.3M -366M -5.38M -36.21M -14.18M -184M -14.39M -14.07M -607M